Exenatide: Another GLP-1 receptor agonist used to manage type 2 diabetes, similar in function to semaglutide
This led to the development of semaglutide, which has a half-life of 6 to 7 days compared to 2 hr for exenatide and 11 to 13 hr for liraglutide.[40,41] The prolonged half-life of semaglutide was achieved by switching the alanine at position 8 with -aminoisobutyric acid, making it DPP-IV resistant,[42] and a fatty acid chain that enhances albumin binding, protecting it from renal clearance and enzymatic degradation.[43] Semaglutide has demonstrated efficacy in lowering blood glucose and promoting weight loss in both obese mice and humans.[4446] GLP-1 analogs exert multiple beneficial effects in humans, including suppression of appetite,[47] reduction of fat mass,[45] and regulation of blood glucose levels.[48] However, limitations remain
Constipation is another driver
The different mechanismsGLP-1 receptor agonist versus central nervous system stimulantcan lead to a complex drug interaction profile
Particles can form from crystallization of the medication, precipitation of inactive ingredients, contamination from the rubber stopper, or introduction of foreign material during use
If a formulation can consistently achieve 20% to 30% sublingual bioavailability, the gap between drops and injections narrows considerably
